INTRODUCTION
Therapeutic proteins, also known as biologics, are ph armaceutical agents created in a laboratory setting to mimic the structure of naturally produced proteins in the body. They may either mimic the natural protein's function or antagonize the function of the natural prot ein. These drugs are produced in living cellular systems, and they have proven to be effective treatment for ma ny diseases including rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases [1] . Unfor tunately, the high costs of therapeutic protein place a heavy financial burden on the healthcare system and limit the number of patients that are able to be covered. For example, monoclonal antibody therapy one type of therapeutic protein is projected to reach $125 billion in global sales by 2020 [2] . As patents on biologic drugs expired, biosimilar drugs were developed and are he lping to address this growing issue. The United States Food and Drug Administration (FDA) defines a biosimilar as "a biological product that is highly similar to and has no clinically meaningful differences from an existing FDAapproved reference product." These drugs are still created using living cells, but the synthesis pathway of the reference biologic is proprietary. Biosimilar deve lopers instead analyze the final biologic and attempt to reverse engineer a feasible synthesis pathway.
The Affordable Care Act created a more efficient licensing pathway for these biosimilar drugs provided it can be proven that the biosimilar drug is not significa ntly different from its reference product in terms of effe ctiveness or safety. The process for biosimilar approval in Europe was established prior to that of the United KaidaYip F et al . Biosimilars: Applications, obstacles, and future
States. The European Medicine Agency (EMEA) and the associated Committee for Medicinal Products for Human Use (CHMP) evaluate data gathered by pharmaceutical companies seeking approval for prospective biosimilars [3] . In both the United States and in Europe, biosimilar dru gs must undergo structural analyses, functional assays, animal studies, and finally clinical studies. Throughout ea ch step of the abbreviated approval process the biosimil ar drug is compared to its reference biologic and assessed for similarity [4] . In contrast, a standard biological product undergoes a more traditional set of trials involving labo ratory and animal testing to determine safety in humans followed by clinical trials.
A study in Europe examining the acceptance of bio similars found that very few patients were willing to swit ch to a biosimilar if they were already taking a biologic. Increases in prevalence of biosimilar treatment are dri ven primarily by new patients that start on a biosimilar first. Even in a new patient population, significant price reductions, sometimes 50% or more, must be in place for physicians to consider prescribing a biosimilar [5] . Market shares for biosimilars are increasing slowly. For example, the filgrastim biosimilar Zarxio held 15% of the United States filgrastim market in 2016 and the in fliximab biosimilar Inflectra held less than 10% of the infliximab market (United States biosimilar market). Gastroenterology has many potential benefits from bio similars in terms of increasing treatment access while reducing treatment costs. Inflammatory bowel diseases and gastrointestinal cancers utilize biologics regularly. Within the endocrinological function of gastroenterology, biosimilar insulin is also an area of active investigation as insulin costs and prevalence of diabetes both continue to increase.
INFLAMMATORY BOWEL DISEASES
The antitumor necrosis factor alpha (TNFα) biologic infliximab is an effective treatment for inflammatory bowel diseases. The PLANETAS study, a phase Ⅰ study, established biosimilar infliximab, CTP13, as having eq uivalent pharmacokinetics with comparable safety and efficacy profiles to its reference infliximab while the PLANETRA study, a phase Ⅲ study, found that CTP13 had equivalent efficacy to reference infliximab after 30 wk of treatment [6, 7] . The patient populations in these studies, however, were patients with ankylosing spond ylitis and rheumatoid arthritis. The PROSITBIO cohort study specifically investigated the safety and efficacy of CTP13 in patients with ulcerative colitis and Crohn's disease. The data showed comparable results to those of similar studies with reference infliximab, but the study did not directly compare the biosimilar with its reference biologic [8] . A prospective study of 210 patients also found that CTP13 is effective in inducing clinical remission in Crohn's disease and ulcerative colitis but noted decreased response to treatment and increased risk of allergic reactions in those previously treated with reference infliximab [9] . A study of 96 patients comparing the ef ficacy of infliximab compared to biosimilar CTP13 in maintaining remission in inflammatory bowel diseases found similar longterm outcomes and safety between the two treatment groups [10] . Additionally, a study on CTP13 in pediatric Crohn's disease reported remission after three doses in 24 of 36 patients and clinical res ponse in 31 of 36 [11] . CTP13 is currently marketed as Re msima™ and Inflectra™.
A doubleblind, parallelgroup study comparing another infliximab biosimilar, SB2, with reference infliximab in 584 patients with rheumatoid arthritis demonstrated similar safety, efficacy, immunogenicity, and pharmacokinetics at weeks 30 and 54 [12, 13] . SB2 is currently marketed as Flixabi ® and approved for treatment of multiple chronic in flammatory diseases including the treatment of Crohn's disease and ulcerative colitis in patients between the ages of 6 and 17.
A 2016 study examined survey responses of infla mmatory bowel disease specialists regarding biosimilars. Out of 118 responses, only 19.5% were not confident with using biosimilars, and 44.4% believed the biosimil ar to be interchangeable with the reference biologic. The primary perceived benefit reported was cost reduction, and the main concern was immunogenicity. A prospective multicenter study done in 2015 similarly elucidates a positive response profile of biosimilars, and further illustrates safety regarding immunogenicity [9] . The overall positive outcomes when comparing biosimil ar infliximab to its reference biologic have improved ph ysicians' attitudes towards biosimilars in the context of treating inflammatory bowel disease.
INTERCHANGEABILITY
In addition to biosimilars, there exist "interchangeable" products. In order for a biosimilar to be considered int erchangeable, it must undergo additional testing. The biosimilar in question must have equal clinical efficacy as its reference product and there must be no changes in safety or efficacy when switching between the biosimilar and its reference product. The purpose of a biosimilar being proven to be interchangeable is that the biosimilar may then be substituted in place of its reference biologic without physician involvement [14] . The risks and concerns involved with this substitution are that switching from a reference biologic to a biosimilar may have reduced efficacy or increased immunogenicity. Data that displ ay similar efficacy, safety profiles, and immunogenicity between a biosimilar and its reference product are not sufficient to determine the effects of switching between the products. While the Canadian Agency for Drugs and Technologies in Health (CADTH) has reported equivalent safety and efficacy in switching from reference biologic to biosimilar in treatment of rheumatologic diseases, the one cohort study examining interchangeability in treatme nt of Crohn's disease and ulcerative colitis had a sample size of eight patients at week 48 following the change to biosimilar infliximab [15] . Six of the eight patients continued in remission, but the small sample size causes difficulty in extrapolating the findings to the general population [16] . The NORSWITCH trial examined the safety and effica cy of switching from reference infliximab to a biosimilar infliximab compared to keeping patients on the reference infliximab. The study was constructed as a noninferior ity study and included patients with six different chronic inflammatory diseases. The trial concluded that switchi ng to biosimilar infliximab was not inferior to continuing reference infliximab [17] . While the study provides a nece ssary foundation for interchangeability studies, it did not control for variables within the patient population and it did not study each disease individually. A prospective study of 133 patients with inflammatory bowel disease measured antibodies to infliximab as well as Creactive protein and erythrocyte sedimentation rate in context of disease activity scores to obtain numerical measureme nts of interchangeability. It found no differences betwe en reference infliximab and biosimilar infliximab, but it also did not directly compare to continuing patients on reference infliximab [18] . A study investigating efficacy, ph armacokinetics, and immunogenicity when switching from reference infliximab to a biosimilar infliximab in pediatric patients with inflammatory bowel disease demonstrated no significant differences compared to continuing therapy with reference infliximab [19] . Additional studies focused on specific diseases and patient populations in the future will continue to advance biosimilars to interchangeable products.
LIMITATIONS
The main concerns raised regarding biosimilars are im munogenicity, efficacy, adverse effects when switching from a biologic to a biosimilar, and possible longterm effects [20] . This issue has been well documented in two recent 2017 trials, comparing the implications of switc hing from an infliximab innovator to biosimilar, over the span of 1 year in IBD patients. With its results showing enhanced clinical effectiveness and an appropriated side effect profile [16, 18] . FDA approval addresses questions regarding immunogenicity and efficacy. Although the approval process for biosimilars is expedited, potential biosimilars must prove equivalent efficacy without addi tional immunogenicity or side effects [21, 22] . In terms of switching between products, studies have shown that switching between two structurally different proteins th at have a similar intended effect is not associated with increased risk for adverse events [23] . Thus, switching be tween proteins that share a nearly identical structure should also present no additional risk. The concern that has yet to be addressed is the potential longterm ef fects. As all other characteristics of biosimilars are com parable to biologics, it seems unlikely that long term ris August 16, 2018|Volume 6|Issue 8| KaidaYip F et al . Biosimilars: Applications, obstacles, and future ks would be substantially different. However, only more time and more data will be able to answer with certainty. The main limitation of biosimilars is patient and physician acceptance with many patients preferring to stay on bio logics and physicians preferring to prescribe biologics.
FUTURE DIRECTIONS
Continuing to manufacture new biosimilars as patents on biologics expire will be the primary means of incre asing biosimilar prevalence. Many biologics used to treat inflammatory bowel disease or gastrointestinal cancers do not have corresponding biosimilars at this time (Table  1) . Overall acceptance of biosimilars of patients will de pend on comfort of physicians educating patients and prescribing biosimilars. Physician comfort will depend on additional clinical trials and increasing the amount of available data. Improving insurance coverage of new bio similars will also increase patient access to biosimilars. Insurance companies are more comfortable covering biosimilars that have been on the market longer, but as more biosimilars become available it is possible that th ey will provide coverage even for new biosimilars.
DISCUSSION
Currently there are seven biosimilars approved in the United States. The most recent, biosimilar bevacizum ab, was approved in September, 2017. In the case of infliximab and its biosimilar, it is likely that greater price differences will have to be seen before physicians will be convinced to switch away from the reference product. The average cost per year for infliximab treatment as of 2012 was $24000 [22] . As of 2016, there was only a 15% price difference between infliximab and its biosimilar. The reluctance of both patients and physicians to switch to a biosimilar may imply that increases in market shares for biosimilars will be a matter of time as more biologic naïve patients are placed on biosimilars to begin their tr eatment regimen. The reluctance of physicians also may affect clinical trials and even patient outcomes through the nocebo effect, which has been documented as cau sing generalized side effects despite a lack of plausible pharmacological mechanism based on the drug itself or side effects more severe than observed when medica tion use is blinded [24, 25] . The way in which a physician dis cusses the effects of a drug with a patient influence the possibility of a nocebo effect. As such, patients receiving biosimilars from physicians who are reluctant to prescribe them may experience more adverse events or decreased treatment efficacy.
Additional studies will also be needed to further ex amine interchangeability of biologics and biosimilars. The case of switching from a biosimilar to a biologic if the biosimilar does not produce significant clinical imp rovement should also be explored, especially consideri ng the number of biologicnaïve patients who may be started on a biosimilar rather than biologic therapy. However, as illustrated above, numerous studies have shown to carry similar efficacy when switching from an original biologic agent to a biosimilar. Biosimilars have great potential to improve access to disease modifying therapies over a wide range of chronic illnesses, exte nding even to some cancers. The more costefficient manufacturing process of biosimilars may also open the way to greater experimentation with pharmacological therapies.
CONCLUSION
Biosimilars have the potential to improve patient acc ess to high level drug therapies as well as alleviate the financial strain that chronic illnesses place upon healt hcare systems worldwide. To accomplish this, however, physicians will need to be more comfortable prescribing biosimilars instead of their reference products and the prices of biosimilars will need to be significantly lower th an their biological counterparts. 
